RxDoctor Payments Data

Matthew Patoka, MD

Family Medicine · Springdale, ARNPI 1053623066

Payments from drug & device makers

$411in general payments, 2019–2025

Across 23 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$120
  • Lilly USA, LLC$119
  • Pfizer$34
  • Braeburn Inc.$29
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$25
  • Bayer$21
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$411100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$411 in reported general payments places this provider in the 45th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$1,937
Medicare patients
53
Services billed
147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$129,288
JardianceEmpagliflozin62$52,839
EliquisApixaban34$37,182
TrulicityDulaglutide28$33,508
MounjaroTirzepatide23$26,172
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$16,755
JanuviaSitagliptin Phosphate11$14,235
EntrestoSacubitril/Valsartan13$14,029
Emgality PenGalcanezumab-Gnlm12$9,145
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,984
Breo ElliptaFluticasone/Vilanterol17$7,050
MyrbetriqMirabegron12$5,378
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl17$3,977
Janumet XrSitagliptin Phos/Metformin Hcl12$3,464
Gabapentin167$2,755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$129,288114 claims
Lilly USA, LLCTrulicity, Mounjaro$119$59,67951 claims
PfizerEliquis$34$37,18234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →